News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

iBio, Inc. (IBIO) Appoints Another IPF Expert, Dr. J. Terrill Huggins, To Clinical Advisory Board


8/1/2014 11:18:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEWARK, DE--(Marketwired - July 30, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has appointed J. Terrill Huggins, M.D. to its clinical advisory board. The board of science and medical experts is assisting iBio in its clinical and product strategy.

Dr. Huggins is a leading clinical investigator in the field of idiopathic pulmonary fibrosis (IPF), and has been the principal investigator or co-principal investigator in more than 20 IPF clinical trials.

"Dr. Huggins's combination of IPF research experience and clinical practice are both directly relevant to our development program," said Terence Ryan, Ph.D., iBio's chief scientific officer.

Data published in 2012 by Dr. Carol Feghali-Bostwick, inventor on the patents licensed by iBio, demonstrate that specific peptides enabled both inhibition and reversal of fibrosis in preclinical mouse models of fibrosis as well as in human skin. iBio is developing a novel therapeutic product for IPF and other fibrotic diseases in collaboration with Dr. Feghali-Bostwick at the Medical University of South Carolina (MUSC). iBio has produced the active pharmaceutical ingredient using its proprietary technology and has made clinical development of this promising product a key priority.

"I look forward to working with the iBio team," said Dr. Huggins. "I believe achieving a substantial advance in the treatment of pulmonary fibrosis is a high priority, and this program has a good chance of delivering that important medical advance."

Dr. Huggins is associate professor of medicine in the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine at the Medical University of South Carolina (MUSC). He also serves as the director of the Interstitial Lung Disease Program at MUSC. His research interests center on interstitial lung disease and particularly IPF. Over the past 10 years, MUSC has become one of the largest IPF clinical trials programs in the U.S., and was the highest enrolling site for both recently completed Phase III trials studying the efficacy of pirfenidone and nintenanib in the treatment of IPF. Dr. Huggins has authored 33 original manuscripts, 100 plus abstracts and national presentations, and has authored 20 book chapters.

Other members of the iBio's clinical advisory board include Richard M. Silver, M.D., one of the world's leaders in clinical care and investigation of systemic sclerosis, and Timothy Blackwell, M.D., an internationally recognized expert in idiopathic pulmonary fibrosis (IPF) and other lung diseases.

About Idiopathic Pulmonary Fibrosis

IPF is a life-shortening lung disease with a rapidly progressing negative impact on quality of life leading to death within an average of three to five years after diagnosis. IPF has a worse survival rate than most cancers except for pancreatic cancer and certain lung cancers.

According to GlobalData, the market across the U.S. and European Union for already existing IPF therapies is expected to grow from $49 million in 2012 to more than $1.1 billion by 2017.

About iBio, Inc.

iBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.

The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com.

FORWARD-LOOKING STATEMENTS

STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.


Investor Relations Contact
Ron Both
Liolios Group, Inc.
Tel 949-574-3860
Email Contact



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES